Ser347
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser347  -  PNN (human)

Site Information
KEIAIVHsDAEKEQE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 460444

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 )
Disease tissue studied:
breast cancer ( 3 , 14 , 15 ) , cervical cancer ( 30 ) , cervical adenocarcinoma ( 30 ) , leukemia ( 18 ) , acute myelogenous leukemia ( 18 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 13 ) , acute megakaryoblastic leukemia (M7) ( 13 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 13 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 13 ) , acute myeloblastic leukemia, without maturation (M1) ( 13 ) , lung cancer ( 5 , 15 , 36 ) , non-small cell lung cancer ( 15 , 36 ) , non-small cell lung adenocarcinoma ( 5 ) , B cell lymphoma ( 13 ) , non-Hodgkin's lymphoma ( 13 ) , follicular lymphoma ( 8 ) , ovarian cancer ( 7 ) , multiple myeloma ( 13 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 19 ) , 293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 35 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 26 ) , 293 (epithelial) ( 33 ) , A498 (renal) ( 28 ) , AML-193 (monocyte) ( 13 ) , BT-20 (breast cell) ( 15 ) , BT-474 (breast cell) ( 3 ) , BT-549 (breast cell) ( 15 ) , Calu 6 (pulmonary) ( 15 ) , CMK (megakaryoblast) ( 13 ) , CTS (myeloid) ( 13 ) , DOHH2 ('B lymphocyte, precursor') ( 13 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 16 ) , Flp-In T-Rex-293 (epithelial) ( 16 ) , GM00130 (B lymphocyte) ( 27 ) , H2009 (pulmonary) ( 15 ) , H2077 (pulmonary) ( 15 ) , H2887 (pulmonary) ( 15 ) , H322M (pulmonary) ( 15 ) , HCC1359 (pulmonary) ( 15 ) , HCC1937 (breast cell) ( 15 ) , HCC2279 (pulmonary) ( 15 ) , HCC366 (pulmonary) ( 15 ) , HCC4006 (pulmonary) ( 15 ) , HCC78 (pulmonary) ( 15 ) , HCC827 (pulmonary) ( 15 ) , HEL (erythroid) ( 13 ) , HeLa (cervical) ( 1 , 6 , 12 , 20 , 25 , 31 , 35 , 37 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 23 ) , HeLa S3 (cervical) ( 23 , 30 , 32 , 34 ) , HOP62 (pulmonary) ( 15 ) , HUES-9 ('stem, embryonic') ( 24 ) , Jurkat (T lymphocyte) ( 21 , 22 , 29 ) , K562 (erythroid) ( 12 , 31 ) , Kasumi-1 (myeloid) ( 13 ) , KG-1 (myeloid) ( 13 , 18 ) , LCLC-103H (pulmonary) ( 15 ) , liver ( 10 ) , MCF-7 (breast cell) ( 3 , 15 ) , MDA-MB-231 (breast cell) ( 15 ) , MDA-MB-468 (breast cell) ( 15 ) , MV4-11 (macrophage) ( 13 ) , NCI-H1395 (pulmonary) ( 15 ) , NCI-H1568 (pulmonary) ( 15 ) , NCI-H157 (pulmonary) ( 15 ) , NCI-H1648 (pulmonary) ( 15 ) , NCI-H1666 (pulmonary) ( 15 ) , NCI-H2030 (pulmonary) ( 15 ) , NCI-H2172 (pulmonary) ( 15 ) , NCI-H322 (pulmonary) ( 15 ) , NCI-H3255 (pulmonary) ( 36 ) , NCI-H520 (squamous) ( 15 ) , NCI-H647 (pulmonary) ( 15 ) , OCI-ly1 (B lymphocyte) ( 8 ) , OPM-2 (plasma cell) ( 13 ) , ovary ( 7 ) , P31/FUJ (erythroid) ( 13 ) , PC9 (pulmonary) ( 5 , 15 ) , PC9-IR (pulmonary) ( 5 ) , RL ('B lymphocyte, precursor') ( 13 ) , RPMI-8266 (plasma cell) ( 13 ) , SH-SY5Y (neural crest) ( 9 ) , SKBr3 (breast cell) ( 14 ) , SU-DHL-6 (B lymphocyte) ( 13 ) , U266 (plasma cell) ( 13 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Treatments:
isoproterenol ( 35 ) , nocodazole ( 30 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

4

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

5

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

8

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

9

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

10

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

11

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

12

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

13

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

14

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

15

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

16

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

17

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

18

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

19

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

20

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

21

Guo A (2011) CST Curation Set: 11983; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

22

Guo A (2011) CST Curation Set: 11847; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

23

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

24

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

25

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

26

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

27

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

28

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

29

Possemato A (2010) CST Curation Set: 9154; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

30

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

31

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

32

Malik R, et al. (2009) Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J Proteome Res 8, 4553-63
19691289   Curated Info

33

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

34

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

35

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

36

Guo A (2007) CST Curation Set: 3631; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

37

Nousiainen M, et al. (2006) Phosphoproteome analysis of the human mitotic spindle. Proc Natl Acad Sci U S A 103, 5391-6
16565220   Curated Info